News

U.S. FDA Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label

Posted: 19 June 2023 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S.…

Pioneering radiotherapy treatment emerging as a new option for cancers spread to lungs

Posted: 19 June 2023 A pioneering radiotherapy treatment developed at Peter Mac is emerging as a new treatment option for cancer that has spread to the lungs, following exciting results in a recent study. Long-term survival data is…

First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Posted: 19 June 2023 Telix today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of…

Lung and heart stem cell research paves way for new COVID-19 treatments

Posted: 15 June 2023 Melbourne researchers have used heart and lung stem cells infected with the virus that causes COVID-19 to better understand how the disease impacts different organs, paving the way for more targeted treatments. The research,…

Why this CEO thinks 454pc growth in his company is just the beginning

Posted: 15 June 2023 Telix Pharmaceuticals has topped the inaugural Financial Review Fast Global list, with international revenue growth at the Melbourne-based, cancer-fighting biotech soaring off the back of a drug approval in the US. The Fast Global…

Telix Opens European Radiopharmaceutical Production Facility

Posted: 13 June 2023 Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in…

RMIT backs Vietnam with new $250m strategic investment fund

Posted: 13 June 2023 Today, in the presence of Australia’s Prime Minister, the Honourable Anthony Albanese MP, RMIT University announced the next phase of its Country Commitment to Vietnam, including a AUD $250 million strategic investment fund. The…

New Eye Clinical Trials Centre to Give Victorians World-First Treatments

Posted: 13 June 2023 Breakthrough Victoria is investing $10 million towards a new world-leading eye clinical trials centre that will provide Victorians with early access to new treatments aiming to prevent and cure blindness. The new eye clinical…

Clinical trials in Australia to use common voice

Posted: 9 June 2023 ARCS Australia has released a white paper to define common terms used in decentralised clinical trials providing a common and consistent language for the sector. The paper was released on day two of the…

Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder

Posted: 9 June 2023 Kinoxis Therapeutics is pleased to announce it has been awarded a UH3 grant by the National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH), which is expected to…

CSIRO invests $25 million to drive biotech innovation

Posted: 9 June 2023 Australia’s national science agency, CSIRO, has invested $25 million up to 2027 in a new program that will harness the building blocks of life to solve intractable problems. Advanced Engineering Biology (AEB) is the latest…

Avecho completes development of TPM-enhanced cannabinoid gummies

Posted: 9 June 2023 Avecho Biotechnology Limited today announced it has completed the development of first generation TPM® gummies containing cannabinoids. TPM cannabinoid gummies out–perform standard products with faster onset and greater magnitude of effect.Gummies are chewable, jelly–like preparations made…

Home

News & opinion

Member Directory

Events